Literature DB >> 3029074

A human purine nucleoside phosphorylase deficiency caused by a single base change.

S R Williams, V Gekeler, R S McIvor, D W Martin.   

Abstract

Purine nucleoside phosphorylase (PNP) deficiency in humans is associated with a severe defect in T-lymphocyte function. The mutant gene was cloned from one PNP-deficient patient who was the offspring of a consanguineous mating. The exons and intron/exon boundaries of the mutant PNP gene were sequenced and compared with the wild-type cDNA sequence. A single base difference was found in the coding region of the mutant gene, a G to A transition in the third exon. This single base mutation alters the codon at position 89 from Glu to Lys, a result which is consistent with previously published peptide mapping data. The patient was demonstrated to be autozygous for the single base mutation on the basis of hybridization of synthetic oligomers to genomic DNA digests. A mammalian expression vector was constructed containing the entire mutant gene under the transcriptional regulation of its own promoter. In another construction, the single base mutation was reverted to the wild-type sequence by in vitro mutagenesis. An isoelectric focusing gel containing extracts of the cells transfected with the mutant and reverted PNP gene was stained histochemically for PNP activity. The proteins from a similar gel were blotted on a nitrocellulose membrane, and immunoreactive human PNP protein was visualized. Cells transfected with the mutant gene contained no human PNP activity, but expressed immunoreactive PNP which focused at an abnormally alkaline pI. Cells transfected with the reverted gene expressed human PNP activity which co-focused with human PNP from a HeLa cell control, proving that the observed single base change was responsible for the loss of catalytic function.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029074

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Sequence and functional characterization of the human purine nucleoside phosphorylase promoter.

Authors:  J J Jonsson; S R Williams; R S McIvor
Journal:  Nucleic Acids Res       Date:  1991-09-25       Impact factor: 16.971

2.  The CpG dinucleotide and human genetic disease.

Authors:  D N Cooper; H Youssoufian
Journal:  Hum Genet       Date:  1988-02       Impact factor: 4.132

3.  Genetic and serological heterogeneity of the supertypic HLA-B locus specificities Bw4 and Bw6.

Authors:  C A Müller; G Engler-Blum; V Gekeler; I Steiert; E Weiss; H Schmidt
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

4.  Selective and synchronous activation of early-S-phase replicons of Ehrlich ascites cells.

Authors:  V Gekeler; J Epple; G Kleymann; H Probst
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

5.  Intron requirement for expression of the human purine nucleoside phosphorylase gene.

Authors:  J J Jonsson; M D Foresman; N Wilson; R S McIvor
Journal:  Nucleic Acids Res       Date:  1992-06-25       Impact factor: 16.971

6.  Molecular analysis of mutations in a patient with purine nucleoside phosphorylase deficiency.

Authors:  M R Aust; L G Andrews; M J Barrett; C J Norby-Slycord; M L Markert
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

7.  Role of ionization of the phosphate cosubstrate on phosphorolysis by purine nucleoside phosphorylase (PNP) of bacterial (E. coli) and mammalian (human) origin.

Authors:  Anna Modrak-Wójcik; Aneta Kirilenko; David Shugar; Borys Kierdaszuk
Journal:  Eur Biophys J       Date:  2007-07-17       Impact factor: 1.733

8.  Genetic variants associated with arsenic susceptibility: study of purine nucleoside phosphorylase, arsenic (+3) methyltransferase, and glutathione S-transferase omega genes.

Authors:  Sujata De Chaudhuri; Pritha Ghosh; Nilendu Sarma; Papiya Majumdar; Tanmoy Jyoti Sau; Santanu Basu; Susanta Roychoudhury; Kunal Ray; Ashok K Giri
Journal:  Environ Health Perspect       Date:  2008-04       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.